Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases

[1]  Ajay N. Jain,et al.  Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.

[2]  G. Giaccone,et al.  Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Chin,et al.  Human and mouse oligonucleotide-based array CGH , 2005, Nucleic acids research.

[4]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[5]  D. Pinkel,et al.  Array comparative genomic hybridization and its applications in cancer , 2005, Nature Genetics.

[6]  Chi-Hung Lin,et al.  Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases—An analysis by comparative genomic hybridization , 2005, Genes, chromosomes & cancer.

[7]  Elena Marchiori,et al.  Breakpoint identification and smoothing of array comparative genomic hybridization data , 2004, Bioinform..

[8]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[10]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[11]  P. V. van Diest,et al.  Comparative genomic hybridisation as a supportive tool in diagnostic pathology , 2003, Journal of clinical pathology.

[12]  J. V. van Meerbeeck,et al.  Determination of the molecular relationship between multiple tumors within one patient is of clinical importance. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Petersen,et al.  Chromosomal imbalances of primary and metastatic lung adenocarcinomas , 2002, The Journal of pathology.

[14]  E. Salminen,et al.  Risk of a new primary cancer among patients with lung cancer of different histological types. , 2001, European journal of cancer.

[15]  B. Jeremic,et al.  Second cancers occurring in patients with early stage non-small-cell lung cancer treated with chest radiation therapy alone. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Devries,et al.  Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. , 2000, Journal of the National Cancer Institute.

[17]  M M Weiss,et al.  Comparative genomic hybridisation. , 1999, Molecular pathology : MP.

[18]  B. Johnson,et al.  Second lung cancers in patients after treatment for an initial lung cancer. , 1998, Journal of the National Cancer Institute.

[19]  P. Carroll,et al.  Genetic alterations in primary bladder cancers and their metastases. , 1998, Cancer research.

[20]  M. Sagawa,et al.  K-ras point mutation occurs in the early stage of carcinogenesis in lung cancer. , 1998, British Journal of Cancer.

[21]  S. Rodenhuis,et al.  K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung , 1993, Cancer.